Zobrazeno 1 - 10
of 169
pro vyhledávání: '"Leonardo A. Meza‐Zepeda"'
Autor:
Baoyan Bai, Jillian F. Wise, Daniel Vodák, Sigve Nakken, Ankush Sharma, Yngvild Nuvin Blaker, Marianne Brodtkorb, Vera Hilden, Gunhild Trøen, Weicheng Ren, Susanne Lorenz, Michael S. Lawrence, Ola Myklebost, Eva Kimby, Qiang Pan-Hammarström, Chloé B. Steen, Leonardo A. Meza-Zepeda, Klaus Beiske, Erlend B. Smeland, Eivind Hovig, Ole Christian Lingjærde, Harald Holte, June Helen Myklebust
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Follicular lymphoma (FL) is the most common indolent type of B-cell non-Hodgkin lymphoma. Advances in treatment have improved overall survival, but early relapse or transformation to aggressive disease is associated with inferior outcome. To
Externí odkaz:
https://doaj.org/article/92e65d15b9924346a5867a14c377ae05
Autor:
Yang Zhou, Partho Sarothi Ray, Jianguo Zhu, Frank Stein, Mandy Rettel, Thileepan Sekaran, Sudeep Sahadevan, Joel I. Perez-Perri, Eva K. Roth, Ola Myklebost, Leonardo A. Meza-Zepeda, Andreas von Deimling, Chuli Fu, Annika N. Brosig, Kjetil Boye, Michaela Nathrath, Claudia Blattmann, Burkhard Lehner, Matthias W. Hentze, Andreas E. Kulozik
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-22 (2024)
Abstract Osteosarcoma is the most common primary malignant bone tumor with a strong tendency to metastasize, limiting the prognosis of affected patients. Genomic, epigenomic and transcriptomic analyses have demonstrated the exquisite molecular comple
Externí odkaz:
https://doaj.org/article/c8a044416b63443ebe99465720d460f3
Autor:
Heidi Maria Namløs, Ksenia Khelik, Sigve Nakken, Daniel Vodák, Eivind Hovig, Ola Myklebost, Kjetil Boye, Leonardo A. Meza‐Zepeda
Publikováno v:
Molecular Oncology, Vol 17, Iss 11, Pp 2432-2450 (2023)
Patients with localised, high‐risk gastrointestinal stromal tumours (GIST) benefit from adjuvant imatinib treatment. Still, approximately 40% of patients relapse within 3 years after adjuvant therapy and the clinical and histopathological features
Externí odkaz:
https://doaj.org/article/5b331ae78b3f4046b28c1408e7ea9d6d
Autor:
Irantzu Anzar, Brandon Malone, Pubudu Samarakoon, Ioannis Vardaxis, Boris Simovski, Hugues Fontenelle, Leonardo A. Meza-Zepeda, Richard Stratford, Emily Z. Keung, Melissa Burgess, Hussein A. Tawbi, Ola Myklebost, Trevor Clancy
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionSarcomas are comprised of diverse bone and connective tissue tumors with few effective therapeutic options for locally advanced unresectable and/or metastatic disease. Recent advances in immunotherapy, in particular immune checkpoint inhi
Externí odkaz:
https://doaj.org/article/53e7fb56ac8c4288a24bd58dd3d4124a
Autor:
Andreas Venizelos, Christina Engebrethsen, Wei Deng, Jürgen Geisler, Stephanie Geisler, Gjertrud T. Iversen, Turid Aas, Hildegunn S. Aase, Manouchehr Seyedzadeh, Eli Sihn Steinskog, Ola Myklebost, Sigve Nakken, Daniel Vodak, Eivind Hovig, Leonardo A. Meza-Zepeda, Per E. Lønning, Stian Knappskog, Hans P. Eikesdal
Publikováno v:
Genome Medicine, Vol 14, Iss 1, Pp 1-18 (2022)
Abstract Background Subclonal evolution during primary breast cancer treatment is largely unexplored. We aimed to assess the dynamic changes in subclonal composition of treatment-naïve breast cancers during neoadjuvant chemotherapy. Methods We perfo
Externí odkaz:
https://doaj.org/article/c8fdf6f22c9d4f50b2aecdfe0b4e304f
Autor:
Heidi M. Namløs, Magne Skårn, Deeqa Ahmed, Iwona Grad, Kim Andresen, Stine H. Kresse, Else Munthe, Massimo Serra, Katia Scotlandi, Antonio Llombart-Bosch, Ola Myklebost, Guro E. Lind, Leonardo A. Meza-Zepeda
Publikováno v:
BMC Genomics, Vol 23, Iss 1, Pp 1-13 (2022)
Abstract Background Osteosarcoma is the most common primary malignant tumour of bone occurring in children and young adolescents and is characterised by complex genetic and epigenetic changes. The miRNA miR-486-5p has been shown to be downregulated i
Externí odkaz:
https://doaj.org/article/b508152fbe6b4d9db3a0cc3f2bf17690
Autor:
Anita Sveen, Bjarne Johannessen, Ina A. Eilertsen, Bård I. Røsok, Marie Gulla, Peter W. Eide, Jarle Bruun, Kushtrim Kryeziu, Leonardo A. Meza-Zepeda, Ola Myklebost, Bjørn A. Bjørnbeth, Rolf I. Skotheim, Arild Nesbakken, Ragnhild A. Lothe
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-18 (2021)
Abstract Background Colorectal cancer is the 2nd leading cause of cancer-related deaths with few patients benefiting from biomarker-guided therapy. Mutation expression is essential for accurate interpretation of mutations as biomarkers, but surprisin
Externí odkaz:
https://doaj.org/article/b34b58a9f5234132b5b1362c2f2bb886
Autor:
Mariaserena Giliberto, Leonardo Miranda Santana, Toril Holien, Kristine Misund, Sigve Nakken, Daniel Vodak, Eivind Hovig, Leonardo A. Meza-Zepeda, Eivind Coward, Anders Waage, Kjetil Taskén, Sigrid S. Skånland
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionMultiple myeloma (MM) is a heterogeneous disease where cancer-driver mutations and aberrant signaling may lead to disease progression and drug resistance. Drug responses vary greatly, and there is an unmet need for biomarkers that can gui
Externí odkaz:
https://doaj.org/article/2b4da978d1fa40c8bdcb5d04f3de4053
Autor:
Mads Bengtsen, Ivan Myhre Winje, Einar Eftestøl, Johannes Landskron, Chengyi Sun, Kamilla Nygård, Diana Domanska, Douglas P. Millay, Leonardo A. Meza-Zepeda, Kristian Gundersen
Publikováno v:
PLoS Genetics, Vol 17, Iss 11 (2021)
Muscle cells have different phenotypes adapted to different usage, and can be grossly divided into fast/glycolytic and slow/oxidative types. While most muscles contain a mixture of such fiber types, we aimed at providing a genome-wide analysis of the
Externí odkaz:
https://doaj.org/article/28df7c301d8940bbab044cb5c92e2b8c
Autor:
Anastas Pashov, Velizar Shivarov, Maya Hadzhieva, Victor Kostov, Dilyan Ferdinandov, Karen-Marie Heintz, Shina Pashova, Milena Todorova, Tchavdar Vassilev, Thomas Kieber-Emmons, Leonardo A. Meza-Zepeda, Eivind Hovig
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Specific antibody reactivities are routinely used as biomarkers, but the antibody repertoire reactivity (igome) profiles are still neglected. Here, we propose rationally designed peptide arrays as efficient probes for these system level biomarkers. M
Externí odkaz:
https://doaj.org/article/b42d87ee4a3c4e5fa4d5e1a1f52e7e9b